X
<

Dentsply Sirona Reported Disappointing 2Q17 Results

PART:
1 2 3 4 5 6
Part 5
Dentsply Sirona Reported Disappointing 2Q17 Results PART 5 OF 6

What Do Analysts Recommend for Dentsply Sirona?

Analysts’ recommendations

Dentsply Sirona (XRAY) released its 2Q17 results on August 9, 2017. Let’s take a look at the recommendations and target prices provided by Wall Street analysts for the dental consumables and equipment leader over the next year.

In a recent Reuters survey, based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona. Around 31% (or five) of the firms gave the company a “hold” rating. Only one of the analysts recommended a “sell” on XRAY stock.

What Do Analysts Recommend for Dentsply Sirona?

Interested in DHR? Don't miss the next report.

Receive e-mail alerts for new research on DHR

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The chart above shows the recommendation summary for Dentsply Sirona over the next year. The consensus 12-month target price for XRAY stock is $67.10, which amounts to an ~21.2% potential return over its price of $55.30 on August 11, 2017.

Target prices

Based on analysts’ recommendations, Dentsply Sirona’s highest 12-month target price is $76.00, representing a maximum one-year return potential of 37.4%. The lowest 12-month target price is $49.00, which represents the lowest one-year return potential of -11.4%.

In July 2017, Jefferies maintained its “buy” target on XRAY stock while raising its price target to $72.00. Credit Suisse raised the price target on XRAY stock to $75.00. In May 2017, Goldman Sachs downgraded Dentsply Sirona’s rating from “neutral” to “sell” and decreased its price target on the stock to $55.00.

Peers Integra LifeSciences (IART), Zimmer Biomet Holdings (ZBH), and Danaher Corporation (DHR) have average broker target prices of ~$56.46, $135.65, and $91.08, respectively. These figures imply returns of 12.2%, 20.6%, and 13%, respectively, over the next 12 months.

Investors interested in gaining industry-focused exposure to Dentsply Sirona can consider the SPDR S&P Health Care Equipment ETF (XHE). Dentsply Sirona comprises ~1.5% of XHE’s portfolio.

In the final part of this series, let’s look at the recent stock price performance of Dentsply Sirona.

X

Please select a profession that best describes you: